Unknown

Dataset Information

0

SARS-CoV-2 hyperimmune intravenous human immunoglobulins neutralizes Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.3 and BA.4/BA.5 for treatment of COVID-19.

ABSTRACT: Our study demonstrates that neither 2020-convalescent plasma (CP) nor 2019/2020-immunoglobulin (IVIG) neutralize Omicron subvariants BA.1 to BA.5. In contrast, hyperimmune 2020-hCoV-2IG lots neutralized Omicron VOCs, similar to 2022-CP from BA.1 breakthrough infections. Therefore, high-titer hCoV-2IG and CP could be evaluated for treatment of high-risk individuals infected with circulating Omicron subvariants.

SUBMITTER: Awasthi M 

PROVIDER: S-EPMC9384659 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Intravenous Human Immunoglobulins Neutralizes Omicron Subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for Treatment of Coronavirus Disease 2019.

Awasthi Mayanka M   Golding Hana H   Khurana Surender S  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20230201 3

Our study demonstrates that neither 2020 convalescent plasma (CP) nor 2019/2020 intravenous immunoglobulin (IVIG) neutralizes Omicron subvariants BA.1 to BA.5. In contrast, 2020 hyperimmune anti-severe acute respiratory syndrome coronavirus 2 IVIG (hCoV-2IG) lots neutralized Omicron variants of concern, similar to results with 2022 CP from BA.1 breakthrough infections. Therefore, high-titer hCoV-2IG and CP could be evaluated for treatment of high-risk individuals infected with circulating Omicro  ...[more]

Similar Datasets

Unknown Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.
| S-EPMC9385487 | biostudies-literature
Unknown Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.
| S-EPMC9258748 | biostudies-literature
Unknown Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants.
| S-EPMC9258774 | biostudies-literature
Unknown Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5.
| S-EPMC9836332 | biostudies-literature
Unknown mouse ACE2 receptor bound to SARS-CoV-2 variant Omicron BA.2.12.1 Spike
| EMPIAR-11180 | biostudies-other
Unknown Impact of mutations defining SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 on Spike function and neutralization.
| S-EPMC10661123 | biostudies-literature
Unknown Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5.
| S-EPMC9239574 | biostudies-literature
Unknown Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
| S-EPMC9511629 | biostudies-literature
Unknown Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.
| S-EPMC9342381 | biostudies-literature
Unknown Neutralizing activity of anti-SARS-CoV-2 hyperimmune immunoglobulins and intravenous immunoglobulins against currently circulating SARS-CoV-2 variants.
| S-EPMC11473157 | biostudies-literature